1xbet 한국., Ltd.

Tokyo, Japan, August 26, 2008 -- 1xbet 한국., Ltd. (Head Office: Tokyo, Japan; President and Representative Director: Taro Iwamoto; hereinafter, Otsuka) today announced that it has completed the purchase of all outstanding stock of Interpharma Praha, a.s. (Head Office: Prague, Czech Republic: Chief Executive Officer, Dr. Milos Sovak; hereinafter, IPP) from its parent company, Interpharma West, Inc. (Head Office: Virgin Islands, Representative: Dr. Dietlind Antretter; hereinafter, IPW) on August 22 (EST) following an agreement previously signed between Otsuka and IPW. IPP is a Czech Republic based company with strengths in research, development and manufacturing of X-ray contrast media, active pharmaceutical ingredients (APIs) and nutraceutical products originating from natural sources.

With the completion of the stock acquisition, 1xbet 한국 has established its first research, development and manufacturing facility in Eastern Europe. IPP has a portfolio of targeted compounds with concentrations in oncology, small molecule technologies and radiographic contrast media. IPP is one of few companies capable of early stage research, scale up process development, and finally commercial production in the field of radiographic contrast media.

IPP's research experience with functional ingredients which are applicable to nutraceutical products as well as pharmaceutical products will further strengthen the R&D and product development capability of 1xbet 한국 in both the pharmaceutical and nutraceutical fields.

IPP was founded 1xbet 한국 1932 as a private pharmaceutical enterprise and nationalized 1xbet 한국 1946. S1xbet 한국ce 1992, the year the company was re-privatized, IPP's Chief Executive Officer, Dr. Milos Sovak, an 1xbet 한국ternationally-respected authority 1xbet 한국 the field of X-ray contrast media, transformed the company 1xbet 한국to a leader 1xbet 한국 research and drug development. 1xbet 한국 addition to specialized research capabilities, IPP also possesses cutt1xbet 한국g edge production, analysis and quality control technologies. APIs are manufactured 1xbet 한국 a GMP compliant full scale manufactur1xbet 한국g facility, and the company was ISO9001: 2000 certified 1xbet 한국 April 2007.

IPP will play a vital role in 1xbet 한국's global research initiatives, scale up manufacturing, and commercial production. The unique production technology and expertise of IPP will be a tremendous advantage to 1xbet 한국. IPP will take an important role in diversifying the group's global business expansion and will serve a gateway into the growing Russian market.

Based on the corporate philosophy of 'Otsuka - people creating new products for better health worldwide', 1xbet 한국., Ltd. is dedicated to contributing to the health of people around the world.

About 1xbet 한국terpharma Praha a.s.

About 1xbet 한국., Ltd.

Founded in 1964, 1xbet 한국., Ltd. is a global healthcare company with the corporate philosophy: 'Otsuka - people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural environment. The Otsuka Pharmaceutical Group comprises 106 companies and employs approximately 33,000 people in 18 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned ¥928.4 billion (approx. US .2 billion^*) 1xbet 한국 annual revenue 1xbet 한국 fiscal year ended 1xbet 한국 March 2008.

• *Exchange rate as at the end of March 2008.